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to Cytomegalovirus Infection
Ghislaine M. Gallez-Hawkins,1 Anne E. Franck,1 Xiuli Li,1 Lia Thao,1 Arisa Oki,2
Ketevan Gendzekhadze,2 Andrew Dagis,3 Joycelynne Palmer,3 Ryotaro Nakamura,2
Stephen J. Forman,2 David Senitzer,2 John A. Zaia1The important role of activating killer immunoglobulin-like receptors (KIRs) in protecting against cytomeg-
alovirus (CMV) reactivation has been described previously in patients undergoing hematopoietic cell trans-
plantation (HCT). More specifically, the presence of multiple activating KIRs and the presence of at least
KIR2DS2 and KIR2DS4 in the donor genotype identified a group of HCT patients at low risk for CMV re-
activation. However, CMV infection still occurs in patients with the KIR protective genotype, and the ques-
tion has been raised as to whether this is related to the lack of KIR expression. In this report, expression of
the KIR2DS2 and KIR2DS4 genes, as measured by mRNA-based quantitative polymerase chain reaction in
both the donor cells and the HCT recipient cells, was studied relative to CMV reactivation. In the control
samples from healthy donors, the median range for KIR2DS2 and KIR2DS4 expression was low, with 35%
of donors considered null-expressers. Interestingly, KIR2DS2 and KIR2DS4 expression was elevated after
HCT compared with donor expression before HCT, and was significantly elevated in CMV viremic compared
with CMV nonviremic HCTrecipients. The CMV seropositivity of donors was not associated with activating
KIR expression, and donor null expression in those with the KIR2DS2 or KIR2DS4 genotype was not pre-
dictive for CMV reactivation in the recipient. After controlling for other transplant factors, including donor
type (sibling or unrelated), transplant source (bone marrow or peripheral blood stem cells), and acute
GVHD grade, regression analysis of elevated KIR gene expression found an association for both KIR2DS2
and KIR2DS4, with a 7-fold increase in risk for CMV reactivation. We speculate that the elevated activating
KIR expression in CMV-viremic HCT recipients is either coincidental with factors that activate CMV or is
initiated by CMV or cellular processes responsive to such CMV infection reactivation.
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Previous reports have emphasized the importance
of natural killer (NK) cells and their killer cell
immunoglobulin-like receptors (KIRs) in controlling
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6/j.bbmt.2011.04.008etic cell transplantation (HCT). More specifically, the
use of donors with more than one activating KIR
(aKIR) gene were associated with a 65% reduction in
CMV reactivation [1,2], and the same effect has been
reported in kidney transplantation [3]. In the HCT
setting, the number of aKIR genes in the donors, but
not in the recipients, has been associated with protec-
tion against CMV reactivation, with the greatest pro-
tective effect when the donor genotype contained .5
aKIR genes or at least a combination of KIR2DS2
and KIR2DS4 [4].
The aKIR genotype profile is not necessarily cor-
related with concurrent expression, however.Whether
aKIR expression predicts protection from CMV and,
conversely, whether the nonexpression of these genes
explains the failure of a KIR2DS2/KIR2DS4 genotype
to protect from CMV infection is unclear. In the pres-
ent work, we evaluated the expression of the donor
able 1. Demographic Data (n 5 134)
ecipient age at transplantation, years, median (range) 42.1 (18.8-63.6)
onor age at transplantation, years, median (range) 42.1 (18.0-71.4)
onor type, n (%)
Sibling donor 87 (65%)
Unrelated donor 47 (35%)
tem cell source, n (%)
BM 24 (18%)
PBSCs 110 (82%)
iagnosis, n (%)
Biol Blood Marrow Transplant 17:1662-1672, 2011 1663KIR2DS2 and KIR2DS4 Activation by CMV InfectionaKIR genes KIR2DS2 and KIR2DS4 in recipients of
allogeneic HCT. We analyzed the effect of the HCT
regimen as well as cell reconstitution with aKIR gene
expression to address the foregoing questions and to
test whether expression levels are modulated by post-
HCT events, such as CMV reactivation or graft-
versus-host disease (GVHD). This report focuses on
activating KIR2DS2 and KIR2DS4 gene expression,
because this dual aKIR genotype appears to be protec-
tive, and examines the expression relative to CMV in-
fection in recipients of allogeneic HCT.
Although KIR expression can be detected by flow
cytometry, the available antibodies do not differentiate
the activating KIR2DS2 and its linked gene, the inhib-
itory KIR2DL2. In the present study, we used an
mRNA-based quantitative polymerase chain reaction
(Q-PCR) method for this purpose. Previous reports
have described specific primers for detecting KIR
alleles for genotyping, which also have been used to
detect mRNA and cDNA by various methods, in-
cluding real-time Q-PCR [5-7]. These methods have
limitations, however, and not all published primers
can amplify KIR cDNA using the Q-PCR method,
especially if the amplified sequence is large (i.e.,
.200-300 bp). In the present work, we developed
a method for quantifying KIR2DS2 and KIR2DS4
gene expression using previously cryopreserved
peripheral blood mononuclear cells (PBMCs) and for
establishing a baseline of aKIR gene expression in
donor samples with a corresponding genotype before
HCT. Activating KIR expression was followed
longitudinally at various times posttransplantation,
and the relationship of aKIR expression to CMV
reactivation and to GVHD was evaluated. We found
that CMV infection, but not GVHD, was associated
with increased aKIR gene expression.Lymphoid 51 (38%)
Myeloid 77 (57%)
Other 6 (5%)
isease status at transplantation, n (%)
First CR/CP 57 (43%)
Later CR/CP 16 (12%)
Relapse 22 (16%)
Induction failure 22 (16%)
MDS, AA, MM, or MPD 17 (13%)
onditioning, n (%)
Fludarabine/melphalan 45 (34%)
Myeloablative 88 (66%)
MV serology, n (%)
Missing 1
D-/R+ 33 (25%)
D+/R- 14 (10%)
D+/R+ 86 (65%)
GVHD grade, n (%)
0-I 53 (40%)
II-IV 81 (60%)
hronic GVHD grade, n (%)
None 21 (16%)
Limited 15 (11%)
Extensive 98 (73%)
A indicates aplastic anemia; CP, chronic phase; CR, complete remis-
on; MDS, myelodysplastic syndrome; MM; multiple myeloma; MPD,
yeloproliferative disorder.MATERIALS AND METHODS
Study Patients
In a previous study, 211 consecutive allogeneic
HCT recipients who underwent transplantation be-
tween 2001 and 2006 were followed for CMV reactiva-
tion for at least 1 year posttransplantation [4]. From
that study, cryopreserved PBMC samples from 134
HCT recipients with the KIR2DS2 or KIR2DS4 geno-
type, or both, were available for further analysis at days
40, 90, 120, 150, and 180 post-HCT. In addition, 81
donor samples were also available, of which 55 were
from donor–recipient pairs. Based on study eligibility,
all HCT recipients were at risk for CMV reactivation
as determined by CMV antibody seropositivity in the
donor, the recipient, or both. All subjects (both donors
and recipients) provided signed informed consent for
research approved by the City of Hope’s Institutional
Review Board, and the use of the leftover specimensfor this study is covered under an Institutional Review
Board protocol. Table 1 summarizes general demo-
graphic and clinical data for the 134 study participants
in terms of median age, transplant type, disease diag-
nosis, myeloablative versus nonmyeloablative condi-
tioning, and GVHD prophylaxis.CMV Reactivation
CMV reactivation was monitored by DNA Q-
PCR on plasma collected twice weekly up to 100
days post-HCT. CMV surveillance was continued at
1- to 2-week intervals in ‘‘high-risk’’ patients based
on clinical management guidelines at City of Hope.
High-risk patients included those with persistent lym-
phopenia, with grade II-IV GVHD, or requiring con-
tinued immunosuppression for anti-GVHD therapy.
Q-PCR was performed essentially as described previ-
ously using CMV-gB DNA as an amplification prod-
uct [8], with a lower limit of detection of 200 genome
copies (gc)/mL of plasma. In addition to Q-PCR test-
ing on plasma, all patients had whole blood cultured
for CMV infection on the same blood specimen using
a shell vial culture method as described previously [9].
In this study, CMV infectionwas defined as evidence of
CMV in blood culture shell vial, plasma Q-PCR, orT
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1664 Biol Blood Marrow Transplant 17:1662-1672, 2011G. M. Gallez-Hawkins et al.CMV histology. Time to CMV reactivation was de-
fined as the day of first CMV-positive Q-PCR (.200
gc/mL), and CMV infection was measured quantita-
tively by plasma DNA Q-PCR.
KIR Genotyping and Expression
The method of Sun et al. [10] was used to identify
the 11 functional non-framework genes (2DS1-
5;3DS1;2DL1-3 and 2DL5;3DL1) and to differentiate
full-length alleles from deleted alleles of KIR2DS4 in
all subjects (Supplemental Figure S1). KIR2DS2 and
KIR2DS4 expression was analyzed essentially as de-
scribed previously [6,11]. In brief, mRNA was
processed from 5  106 PBMCs using the RNeasy
Mini Kit (Qiagen, Valencia, CA), followed by DNAse
treatment and first-strand cDNA synthesis using Su-
perscript II and oligo dT (Invitrogen, Carlsbad, CA).
The RNA was degraded by the addition of Rnase H
(Invitrogen). The cDNA equivalent of 125 ng of total
RNA was used for each amplification reaction. The
synthetic oligonucleotides (Integrated DNA Technol-
ogies, Coralville, IA; http://idtdna.com) were designed
with publicly available KIR sequences (Genbank:
http://ncbi.nlm.nih.gov and the IPD-KIR Sequence
database: http://ebi.ac.uk/ipd/kir) and overlapped
exons to ensure RNA sequence amplification. SYBR
Green was used for detection with the melting point
dissociation curves as confirmation of specificity
(Supplemental Figure S2). Actin amplification served
as a control (with a minimum cycle threshold value of
30 or 1024 genome copies). The data presented in
this paper are expressed as copy number/1106b-actin
copies. The reactions were performed using TaqMan
Universal Master Mix and a model 7900 Q-PCR ana-
lyzer (Applied Biosystems,Warrington, UK). The fol-
lowing primers were used:
KIR2DS2: position: 198-454 NM_012312.2; size:
257 bp [6]Forward (exons 3-198): 50 TGCACAGAGAGG
GGAAGTA 30
Reverse (exons 4-454): 50 CACGCTCTCTCC
TGCCAA 30
KIR2DS4: position 374-593 NM_012314.3; size
220 bp
Forward (exons 3-374): 50 CAGTTGTCAGCT
CCCAGTGA 30
Reverse (exons 4-593): 50 CCTGGAATGTT
CCGTTGATG 30
B-ACTIN: position 317-504 NM_001101.3; size
188 bp
Forward (exons 3-317): 50 ACTGGGACGACA
TGGAGAAA 30
Reverse (exons 4-504): 50 TAGCACAGCCTGG
ATAGCAA 30The primers used to amplify KIR2DS4 cDNA can-
notdistinguishbetween the full-length anddeletionmu-
tants. The amplified sequences of KIR2DS2 and
KIR2DS4 were verified by sequencing, and the corre-
sponding products were confirmed. The primers de-
tected all KIR2DS2 and KIR2DS4 alleles except
2DS2*00104,2DS4*0040101, and2DS4*013.Although
these 3 alleles could not be analyzed for expression, they
are rare andwerenot identifiedbygenotype inourHCT
cohort.
Statistical Analysis
GraphPad Prism 5 software (GraphPad Software,
La Jolla CA) was used for the analysis of CMV DNA
Q-PCR results. All other analyses were performed us-
ing SAS 9.25 (SAS Institute, Cary, NC) and S-PLUS
(Insightful, Seattle, WA). The Mann-Whitney U test
was used to compare 2 samples, the Kruskal-Wallis
test for more than 2 samples, and the Wilcoxon
signed rank test for paired data. Contingency tables
were analyzed using the Fisher exact test. To evaluate
whether the time to CMV reactivation was a factor in
the expression of KIR2DS2 and KIR2DS4, Kaplan-
Meier estimates were generated using the log-rank
test. Logistic regressionwas performed and tested using
theWald test. All tests were 2-sided, and the cutoff for
statistical significance was .05.RESULTS
Patient Demographics
The material used in this study was cryopreserved
PBMCs of the appropriate genotype collected from
a previous study, as described in Materials and
Methods. The data presented in Table 1 indicate
that our study subset of 134 patients did not differ sig-
nificantly from the total study population described
previously in terms of HCT parameters [4]. Specifi-
cally, median donor age (42 years) and recipient age
(42 years), type of transplants (sibling donor, 65%; un-
related donor, 35%), and diagnoses (lymphoid, 38%;
myeloid, 57%) were similar in the subset and the full
study population. The same was true for donor/recip-
ient CMV seropositivity (D1/R1, 65%; D1/R-, 10%;
D-/R1, 25%) and acute GVHD (aGVHD) grade
(0-I, 40%; II-IV, 60%). Of the 134 subjects, 98
(73%) became CMV viremic or had CMV-associated
disease post-HCT as demonstrated by PCR, blood
culture, or histopathology, and 36 (27%) were non-
viremic (NV).
KIR2DS2 and KIR2DS4 Expression by mRNA
Q-PCR in Control Samples
KIR expression in 81 donor samples, collected af-
ter treatment with granulocyte colony-stimulating
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for KIR2DS2 and 0-1.3  104 EU for KIR2DS4,
with median values of 72 EU and 80 EU, respectively
(Figure 1). The KIR2DS4d mutant was identifiable by
genotyping but not by specific mRNA expression;
thus, the overall expression of KIR2DS4 irrespective
of allele is shown. The median expression of both acti-
vating KIR genes in donor samples was similar, as was
the percentage of null-expressers (35% for KIR2DS2
and 38% for KIR2DS4). Of note, among the donors
with both KIR2DS2 and KIR2DS4 expression, dual
KIR expression occurred in 50% of the subjects, with
no predominance of either gene. Thus, we established
a baseline of KIR expression in the donor group, which
could be compared with KIR2DS2 and KIR2DS4 ex-
pression levels post-HCT.
Because our hypothesis stated that aKIR expres-
sion plays a role in protection against CMV reactiva-
tion, we examined whether the CMV serology of the
donor, as evidence of latent CMV infection, might
have affected KIR expression. We dichotomized
KIR2DS2 and KIR2DS4 expression into D- and D1
serology groups. The median aKIR expression in the
D- and D1 cells was not statistically significantly dif-
ferent by the Mann-Whitney test, suggesting that
CMV serology of the donor does not ultimately affect
KIR expression (results not shown).
KIR2DS2 and KIR2DS4 Expression in Donor–
Recipient Pairs Is Elevated after HCT
To determine whether KIR2DS2 and KIR2DS4
expression is affected after transplantation, we exam-
ined aKIR levels in donor–recipient pairs. Because
complete chimerism was achieved in 95% of HCT re-
cipients by day 30 post-HCT, we analyzed the donors’2DS2 2DS4 
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Figure 1. KIR2DS2 (circles) and KIR2DS4 (squares) expression by
mRNA-based Q-PCR in donors. KIR2DS2 and KIR2DS4 expression is
reported only in the presence of the corresponding genotype. The
copy number for each subject was normalized to 1 106 b-actin copies,
and the median copy number is shown at the top of each group. Null-
expressers are represented as log 100 5 1 on the y-axis.KIR profiles for KIR expression in the recipients [12].
Each recipient was represented by the mean EU value
of multiple samples collected at the specific times after
HCT (Figure 2). Overall, expression of both
KIR2DS2 (Figure 2A) and KIR2DS4 (Figure 2B)
was significantly elevated after HCT. The median
values in 25 KIR2DS2 donor–recipient pairs were
194 EU for donors and 517 EU for recipients (P 5
.02), and those in 51 KIR2DS4 pairs were 412 EU
for donors and 2041 for recipients in (P \ .0001).
Thus, Q-PCR results on mRNA purified from
PBMCs revealed elevated KIR2DS2 and KIR2DS4
levels after HCT. More important, KIR2DS4 levels
were significantly higher at days 40-90 post-HCT
compared with the corresponding donor levels (me-
dian, 310 EU for donors vs 894 EU for recipients in
42 pairs; P 5 .0025) (Figure 2D), but KIR2DS2 levels
were not (Figure 2C).0 
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Figure 2. KIR2DS2 and KIR2DS4 levels in donor–recipient pairs. The
aKIR levels are reported for the donor before infusion (gray) and for the
recipient after infusion (black). The copy number for each subject was
normalized to 1  106 b-actin copies, and the median copy number is
shown at the top of each group. The mean values of all samples per re-
cipient after HCTare shown in A and B, and the means of all samples per
recipient before day 90 post-HCTare shown in C and D. (A) KIR2DS2
levels for 25 donor–recipient pairs analyzed using theWilcoxon paired-
rank test (P 5 .02). (B) KIR2DS4 levels for 51 donor–recipient pairs an-
alyzed using the Wilcoxon paired-rank test (P\ .0001). (C) KIR2DS2
levels for 22 donor–recipient pairs analyzed using the Wilcoxon
paired-rank test (P 5 .21). (D) KIR2DS4 levels for 42 donor–recipient
pairs analyzed using the Wilcoxon paired-rank test (P \ .0025).
Null-expressers are represented as log 100 5 1 on the y-axis.
01
2
3
4
5
6
p=0.0096* p=0.0573
NV NVViremic Viremic
2DS2 2DS4
117 232 386 769
K
IR
 
cD
N
A 
eq
u
iv
al
en
ts
 
pe
r
 
1e
6
-
a
ct
in
 
eq
u
iv
a
le
n
t (
L
o
g)
0
1
2
3
4
5
6
p=0.33p=0.0068* p=0.1253
NV NVNVViremic Viremic Viremic
2DS4 2DS4/2DS4d 2DS4d
549 2480 856 1561 36 94
K
IR
 
cD
N
A 
eq
u
iv
al
en
ts
 
pe
r
 
1e
6
β-
a
ct
in
 
eq
ui
v
a
le
n
t (
L
o
g)
0
1
2
3
4
5
NV Viremic
2DS2+2DS4 genotype
2DS2 2DS4
215 16024 173
NV Viremic
p=0.13 p=0.10
K
IR
 
cD
N
A 
eq
ui
va
le
n
ts
 
pe
r
 
1e
6
β-
a
ct
in
 
eq
u
iv
a
le
n
t (
L
o
g)
Figure 3. KIR2DS2 and KIR2DS4 expression by mRNA-based Q-PCR
in HCT recipients. The samples from NV subjects are represented by
open symbols; samples from viremic subjects, by solid symbols. KIR2DS2
is represented by circles; KIR2DS4, by squares. The mean value for each
patient is reported, with KIR expression values reported only if the cor-
responding donor KIR genotypewas present. The copy number for each
subject was normalized to 1  106 b-actin copies, and the median copy
number is shown at the top of each group. The Mann-Whitney U test
was performed to establish P values between theNVand viremic groups.
(A) Overall expression of either KIR 2DS2 or KIR2DS4 in the NV and
viremic groups. (B) Differentiation between expression of KIR2DS4
and of the deletion mutant KIR2DS4d. (C) Results for recipients receiv-
ing both genotypes together from donor cells. The null-expressers are
represented as log 100 5 1 on the y-axis.
1666 Biol Blood Marrow Transplant 17:1662-1672, 2011G. M. Gallez-Hawkins et al.Although 6/26 KIR2DS2 and 13/51 KIR2DS4 do-
nors were expression-negative before HCT, in some
recipients there was no expression, and thus KIR ex-
pression level in donor cells could not predict KIR ex-
pression levels in recipients. This is illustrated in
Figure 2A for KIR2DS2, where the 2 recipient KIR
null-expressers (R-) were characterized by KIR D1/R-
and D-/R-, and KIR2DS4 results were characterized
by 4 recipient KIR null-expressers as follows: D-/R-,
D1/R-, D-/R-, andD-/R-. This donor–recipient paired
group clearly shows that the 23%-25% null-expressers
in donor cells decreased to 8% null-expressers in the
recipient cells and demonstrates that transplantation
activated KIR expression in HCT recipients.
KIR2DS2 and KIR2DS4 Expression and CMV
Reactivation after HCT
To determine whether CMV reactivation detected
after HCT affected KIR2DS2 and KIR2S4 expression,
HCT recipients were dichotomized as viremic or NV
(Figure 3A). The expression of KIR2DS2 was signifi-
cantly up-regulated in the viremic group, with median
values of 232 EU compared with 117 EU in the NV
group (P 5 .01, Mann-Whitney U test). This up-
regulation was less pronounced for KIR2DS4 expres-
sion (median, 769 EU for viremic subjects vs 386 EU
for NV subjects; P 5 .06). However, when the HCT
recipients were grouped according to donor genotype,
the viremic group demonstrated significantly higher
full-length KIR2DS4 expression (P 5 .007), whereas
heterozygotes for KIR2DS4 and KIR2DS4d mutants
(P 5 .33) or KIR2DS4d (P 5 .13) did not
(Figure 3B). Of note, the latter group, consisting of
the deletion mutant, expressed mRNA at extremely
low levels, with median values more than 10-fold less
than those in the expressed KIR2DS4. These findings
underscore the importance of detecting deletion mu-
tant alleles that do not express KIR receptors. Of
note, viremic HCT recipients with a dual KIR2DS2–
KIR2DS4 donor genotype also exhibited up-
regulated expression, although this was increase not
statistically significant (Figure 3C).
CMV disease occurs in 10% of patients with CMV
reactivation in our institution. We investigated
whether KIR expression differed in patients who de-
veloped CMV disease and those who did not. The re-
sults are shown in Table 2 for KIR2DS2 (3 patients
with CMV disease and 49 viremic patients) and
KIR2DS4 (4 patients with CMV disease and 55 vire-
mic patients). Overall, median KIR expression was
lower in patients with CMV disease and significantly
lower in those with KIR2DS2 expression (P 5 .0105).
Time Course of KIR Expression Post-HCT
Blood samples were available at days 40, 90, 120,
150, 180, and 360 post-HCT. This sampling schedule
Table 2. KIR Expression in Patients with CMV Disease and Patients with Viremia
KIR2DS2 KIR2DS4
CMV Disease Viremia P Value* CMV Disease Viremia P Value*
Number of patients 3 49 4 55
Mean expression 7.97 708.14 2136.91 4530.6
Median expression 0 306.96 .0105 1404.99 2164.41 .5633
Standard error 4.6 29.55 501.64 127.23
*Mann-Whitney U test.
Biol Blood Marrow Transplant 17:1662-1672, 2011 1667KIR2DS2 and KIR2DS4 Activation by CMV Infectionallowedus to analyze the impact of time on aKIRexpres-
sion after HCT. The Kruskal-Wallis test and Dunn’s
multiple-comparison test were performed on each
data set: KIR2DS2 NV versus KIR2DS2 viremic
(Figure 4A) andKIR2DS4NVversusKIR2DS4 viremic
(Figure4B).Recipientswithonly theKIR2DS4dmutant
genotype were not included in the analysis. The P values
showno significant differences according to time among
the group of expressers within each subgroup.KIR
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Figure 4. Time course of KIR expression post-HCT in NV and viremic subje
40, 90, 120, 150, 180, and 360 post-HCT. The presence of at least one full-lengt
for KIR2DS2 expression in NV subjects and viremic subjects (Mann-Whitney P v
subjects (Mann-Whitney test). The median values are depicted above each coInmost cases, CMV reactivation occurred between
day 40 and day 90 post-HCT. To explore whether
KIR expression differed between NV and viremic pa-
tients during that critical period, we compared
KIR2DS2 expression in NV and viremic patients at
days 40-90 post-HCT and detected no statistically
significant difference. We did the same for KIR2DS4
expression. Analyzing KIR expression post-HCT
without regard for the time of CMV reactivation2DS2 
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groups.KIR Expression Status before CMV Reactivation
To establish whether KIR2DS2 or KIR2DS4 ex-
pression before CMV reactivation could influence
CMV outcome, we generated a cumulative incidence
curve for CMV reactivation for expressers and null-
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Figure 5. Effect of KIR expression status before CMV reactivation. (A)
The percent cumulative CMV incidence in the presence or absence of
KIR2DS2 expression before CMV reactivation (P 5 .45, log-rank test).
(B) The same plot applied to KIR2DS4 (P 5 .51, log-rank test). (C)
Expression (.0) for KIR2DS2, KIR2DS4, or KIR2DS2 1 KIR2DS4
before CMV reactivation (P 5 .04, log-rank test).expression data were available only on or after day 40
post-HCT, no CMV reactivation event occurring be-
fore day 40 was included in this analysis; however, KIR
expression data for day 40 post-HCT with CMV reac-
tivation at the same time were included. CMV reacti-
vation occurred in 42% of KIR2DS2 null-expressers
versus 54% of expressers and in 57% of KIR2DS4
null-expressers versus 51% of expressers. Log-rank
test P values demonstrate no difference in expression
of specific aKIRs before reactivation in HCT recipi-
ents with CMV reactivation (Figure 5A and B). How-
ever, analysis of recipients with both KIR2DS2 and
KIR2DS4 expression (Figure 5C) shows that CMV re-
activation occurred in only 22% of the patients
(P 5 .04).
HCT Variables Affecting KIR2DS2 and KIR2DS4
Expression
Having identified up-regulation of KIR2DS2 and
KIR2DS4 expression in CMV viremic subjects, we
next examined whether this could be related to other
allogeneic HCT variables, including donor type,
transplant source, diagnosis, disease status at trans-
plantation, conditioning regimen, CMV serology (do-
nor/recipient), and aGVHD and chronic GVHD. As
shown in Table 2, the median expression of KIR2DS2
(P5 .0004) and KIR2DS4 (P5 .003) was significantly
lower in recipients of matched unrelated donor trans-
plants than in recipients of sibling donor transplants.
In addition, stem cells collected from the bone marrow
(BM) were associated with decreased median expres-
sion of KIR2DS2 (P 5 .04) and KIR2DS4 (P 5 .03).
BM contains pluripotent stem cells that give rise to
all classes of blood cells, and the low levels of NK cells
could explain the low aKIR expression detected. In ad-
dition, in this cohort, BM was the stem cell source in
a higher percentage of unrelated matched donors
(33%) compared with sibling donors (9%), which ex-
plains the association of low KIR expression with
both BM and unrelated matched transplant recipients
(P 5 .0005). Also of note, neither aGVHD grade nor
chronic GVHD grade had a significant effect on KIR
expression.
Multivariate Analysis Using CMV Viremia As
Outcome
Our sample population was identified strictly by
genotype KIR2DS2 (74 subjects) and/or KIR2DS4
(84 subjects), and our model analyzed each genotype
independently with a baseline set at zero expression
for each KIR type. As shown in Table 3, donor type
(P 5 .0004 for KIR2DS2; P 5 .0002 for KIR2DS4)
and transplant source (P 5 .04 for KIR2DS2; P 5
.03 for KIR2DS4) affected KIR expression, but
aGVHD had no effect on KIR expression. However,
because aGVHD grade is an independent predictor
Table 3. KIR Expression Level by Predictor Variable Level
Predictor Variable
KIR2DS2 Expression* KIR2DS4 Expression†
Median (Range) P‡ Median (Range) P‡
Donor type
Sibling donor 346 (0-15,624) .0004 2302 (0-89,328) .0002
Unrelated donor 95 (0-701) 769 (0-8304)
Stem cell source
BM 94.5 (0-1038) .04 834 (15-4863) .03
PBSCs 232 (0-15,624) 2053.5 (0-89,328)
Diagnosis
Lymphoid 178 (0-2265) .53 1561 (0- 15,107) .91
Myeloid 228 (0-15,624) 1488 (0- 89,328)
Other 1 (0-1038) 910 (104-8304)
Disease status at transplantation
First CR/CP 188.5 (0-15,624) .96 2066 (0-15,107) .46
Later CR/CP 224 (6-1254) 863 (15-2725)
Relapse 232 (0-2265) 2209.5 (81-5224)
Induction failure 178 (0-1769) 1235 (0-27,388)
MDS, AA, MM, or MPD 194 (0-6648) 2041 (104-89,328)
Conditioning
Fludarabine/melphalan 225.5 (0-2265) .75 2033 (0-39,860) .83
Myeloablative 214.5 (0-15,624) 1383 (0-89,328)
CMV serology
D-/R+ 76 (0-1758) .03 1452 (0-8304) .75
D+/R- 128 (0-15,624) 2079 (0-5005)
D+/R+ 300 (0-10,023) 1449 (0-89,328)
aGVHD grade
0-I 188.5 (0-1758) .17 1110 (0-39,860) .55
II-IV 268.5 (0-15,624) 1561 (0-89,328)
Chronic GVHD grade
None 321 (0-1769) .53 1839 (0-27,388) .83
Limited 300 (0-1254) 1226 (0-5224)
Extensive 194 (0-15,624) 2033 (0-89,328)
AA indicates aplastic anemia; CP, chronic phase; CR, complete remission; MDS, myelodysplastic syndrome; MM; multiple myeloma; MPD, myeloprolif-
erative disorder.
*KIR2DS2 genotype.
†KIR2DS4 genotype.
‡Kruskal-Wallis test.
able 4. Multivariate Logistic Regressions—Probability
odel, CMV Status: Viremic
Predictor n OR (95% CI) P Value n
IR2DS2 expression* .04† 74
0 10 (baseline)
>0 64 7.16 (1.51-33.9) .01
onor type
Unrelated matched donor 28 (baseline)
Sibling donor 46 1.00 (0.29-3.48) 1.00
tem cell source
BM 14 (baseline)
PBSCs 60 3.89 (0.96-15.8) .06
GVHD
0-I 28 (baseline)
II-IV 46 1.93 (0.61-6.12) .27
IR2DS4 expression‡ .009† 84
0 5 (baseline)
>0 79 6.69 (0.88-51.0) .07
onor type
Unrelated matched donor 29 (baseline)
Biol Blood Marrow Transplant 17:1662-1672, 2011 1669KIR2DS2 and KIR2DS4 Activation by CMV Infectionof CMV viremia, we included all 3 variables into amul-
tivariate logistic regression model, the results of which
are presented in Table 4.
The odds ratio (OR) for a patient with KIR2DS2
expression .0 was 7-fold greater in the viremic pa-
tients (OR, 7.16; 95% confidence interval [CI], 1.51-
33.9). When the logistic regression included donor
type (OR, 1.00; 95% CI, 0.29-3.48), transplant source
(OR, 3.89; 95% CI, 0.96-15.8), and aGVHD (OR,
1.93; 95% CI, 0.61-6.12), the model’s goodness of fit
remained significant (P 5 .04).
Similarly, the OR for KIR2DS4 expression.0 was
6.69 in the viremic patients (95% CI, 0.88-51.0; P 5
.07). When donor type (OR, 1.00; 95% CI, 0.29-3.46),
transplant source (OR, 5.08; 95% CI, 1.27-20.3), and
aGVHD (OR, 4.61; 95% CI, 1.46-14.6) were included
in the model, the goodness of fit was P5 .009.Sibling donor 55 1.00 (0.29-3.46) 1.00
tem cell source
BM 14 (baseline)
PBSCs 70 5.08 (1.27-20.3) .02
GVHD grade
0-I 31 (baseline)
II-IV 53 4.61 (1.46-14.6) .009
KIR2DS2 genotype.
Goodness of fit of the model.
KIR2DS4 genotype.KIR Expression and HLA Ligands
Expression of aKIR can be modulated by the pres-
enceofHLA-specific ligand ineither thedonoror the re-
cipient. Whereas KIR2DS2 binds with HLA-C1 with
weak affinity, KIR2DS4 can bind tomultiple ligands, in-
cluding HLA-A*11:01, -A*11:02, -C*02, -C*05, -C*14,T
M
K
D
S
a
K
D
S
a
*
†
‡
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C1/C1 was present in 16% of donors and in 22% of re-
cipients,whereasKIR2DS2 ligandC1/C2waspresent in
41% of donors and in 32% of recipients. HLA-A*11:01
was present in 27% of KIR2DS4-positive donors and in
18% of the recipients. The other HLA-C ligands were
pooled together because of their scarcity (in only 8%
of donors and 17% of recipients). Statistical analysis of
the proportions of subjects expressing KIR in the
presence or absence of ligands by theFisher exact test re-
vealednodifferences, evenwhen subgroupsweredichot-
omized into NV and viremic patients (Supplemental
Table 1). These findings suggest that aKIR expression
does not seem to be driven by the presence of ligands;
however, the study population is too small to enable val-
idation of the power of the statistical test.DISCUSSION
The presence of aKIR genes in an HCT donor has
been shown to play an important role in the protection
against such events as poor graft function [14], leukemic
relapse [15,16], andCMVreactivation [4]. Aprevious re-
portdemonstrating aprotectiveeffectonCMVinfection
in HCT recipients with a donor with both a KIR2DS2
and a KIR2DS4 genotype found that nearly one-half
of the donors with this protective genotype still experi-
enced CMV reactivation. Thus, it was hypothesized
that failure of protection could be explained by altered
expression of these KIR genes [4]. Here, we focused on
expression ofKIR2DS2 andKIR2DS4, and investigated
whether their expression correlated with protection
against CMV reactivation. KIR expression was assessed
byQ-PCR of purified mRNA obtained at intervals dur-
ing the major risk period for CMV reactivation after
HCT.
We chose Q-PCR because it can differentiate
KIR2DS2 and KIR2DL2, and because it provides
a quantitative approach to statistical analysis. Expres-
sion data were normalized to b-actin mRNA EU.
Using this quantitative method, we assessed the overall
expression of the 2 KIR genes in relation to clinical
events afterHCT.Wemadeno attempt to discriminate
between the specific contribution of NK cells or
T cells; thus, KIR expression could come from both
cell types. Because of sample limitations, we are unable
to reportNKandTcell counts for each sample, and the
up-regulation of KIR expression could be the result of
a simple increase in NK or T cell number. We could
have used other framework KIRs, such as KIR2DL4
and KIR3DL2, as reference genes to evaluate specific
KIRup-regulation, and theseKIRsmerit further study.
The data demonstrate that in donor cells, the ex-
pression of KIR2DS2 and KIR2DS4 varies among
genotype-positive healthy individuals (donors), with
some expressers and some null-expressers.Under thesedonor conditions, expression of these genes was at low
levels (median, 72 and 80 EU, respectively), and ap-
proximately 35% of these healthy donors were null-ex-
pressers. The donor’s CMV serology had no affect on
KIR expression. However, after HCT, expression of
KIR2DS2 andKIR2DS4was up-regulated inHCT re-
cipients. In paired donor–recipient samples from
matched related donor (MRD) allogeneic HCT, up-
regulation of KIR2DS4 expression was seen between
day 40 and day 90 post-HCT (P 5 .0025), the earliest
time period examined (Figure 2). Of particular note,
the expression levels in the recipients of grafts from un-
related matched donors were significantly lower than
those in MRD recipients (Table 2). This is consistent
with the overall better outcome ofMRD transplant re-
cipients [17] and suggests that receptor–ligand interac-
tions merit further study to delineate these differences.
In addition, BMwas a more frequent transplant source
than PBSCs in unrelatedmatched donors (33%vs 9%),
which possibly could account for the low KIR expres-
sion, given that BM contains 20-fold fewer NK cells
in the graft compared with PBSCs [18].
We next examined whether this increased KIR ex-
pression inHCTrecipientswas associatedwith specific
clinical events after HCT, such as CMV reactivation.
Figure 3 plots the mean expression of KIR2DS2 and
KIR2DS4 per subject in the NV and viremic groups.
Expression of both KIRs was significantly higher in
the viremic group. The KIR2DS4d mutant, which is
not expressed on the cell surface, demonstrated signif-
icantly lower levels of mRNA transcripts (median, 36
EU in the NV group) than the full-length alleles (me-
dian, 549 EU in theNVgroup). To determine whether
the CMV reactivation was related to nonexpression of
these KIR genes before reactivation, we examined cu-
mulative mean expression levels as well as expression
at multiple time points before and after CMV reactiva-
tion. As shown in Figure 3, the mean KIR expression
levels at all time points were significantly higher in
the viremic group; however, analysis of the time course
of expressionpost-HCTrevealed no statistically signif-
icant differences between the viremic and NV groups.
This likely is related to the varying times of CMV reac-
tivation post-HCT. Of note, CMV infection has been
associated with greater expression of NK cells [19],
whichmight help explain the increased KIR expression
seen in the viremic group.
We hypothesized that if aKIR expression affected
CMV reactivation, then we should see a difference in
the cumulative incidence of CMV infection in the ex-
presser and null-expresser groups. However, as shown
in Figure 5, we found no difference in the cumulative
incidence of CMV reactivation in these 2 groups
(42% vs 54% for KIR2DS2 null-expressers and ex-
pressers, respectively, and 57% vs 51% for KIR2DS4
null-expressers and expressers, respectively). The ratio
of null-expressers for KIR2DS2 was 5 of 21(19%) and
Biol Blood Marrow Transplant 17:1662-1672, 2011 1671KIR2DS2 and KIR2DS4 Activation by CMV Infectionthat for KIR2DS4 was 4 of 25 (14%), and, as shown
previously (Figure 3), the NV patients actually had
lower aKIR expression. However, CMV reactivation
occurred in only 22% of the patients who expressed
both KIR2DS2 and KIR2DS4 before onset of CMV
infection. Thus, we suggest that expression of multiple
aKIRs, such as KIR2DS2 and KIR2DS4, may protect
against CMV reactivation, strengthening the conclu-
sion of our earlier study based on genotyping [4].
We then addressed the question of whether the up-
regulation of aKIR expression was actually a response
to cofactors associated with CMV, such as GVHD.
To check whether this or other transplant factors
were responsible for KIR up-regulation, we analyzed
KIR expression levels against various transplant vari-
ables (Table 2). The variables donor type (sibling vs
unrelated matched donor) and transplant source (BM
vs peripheral blood stem cells [PBSCs]) significantly
affected KIR expression level. These 2 variables are re-
lated, in that BM does not contain mature NK or
T cells and is frequently the transplant source in unre-
lated matched HCT. In contrast, we found no statisti-
cally significant association between KIR expression
level and severity of aGVHD. In amultivariate analysis
that included the aforementioned transplant predictors
of CMV viremia (Table 4), KIR2DS2 and KIR2DS4
expression.0 was still predictive of viremia as an out-
come. aGVHDgrade II-IV is known to be significantly
associated with CMV viremia [4]; nevertheless, in the
present study, aKIR expression was associated only
with CMV infection, not with aGVHD per se. Thus,
we concluded that several factors can influence KIR
gene expression post-HCT and aGVHD has little in-
fluence, but CMV infection provides a strong stimulus
for KIR2DS2 and KIR2DS4 expression.
The presence of HLA ligands specific to KIR has
been shown to drive KIR expression into a ‘‘missing
self’’ recognition and lead to a proliferation ofNK cells
to eliminate stressed, virally infected, or transformed
cells. Activating and inhibitory KIRs are the result of
an evolutionary repertoire of receptors that bind
both host and pathogen-encoded ligands [20]. The li-
gand for KIR2DS2 is HLA-C1 [21]. For KIR2DS4,
a variety of ligands that bind with varying affinities
have been described by Graef et al. [13], including
HLA-A*1101, -A*1102, -C*16, -C*14, -C*05, and
-C*02. Whether the presence of ligands specific to
KIR2DS2 and KIR2DS4 was a key factor in the KIR
expression in our small cohort of patients is not clear.
Interestingly, we detected increasedmRNA levels after
HCT, with the highest levels in the viremic subjects.
Early reports have demonstrated that full effector
function of NK cells requires triggering of their acti-
vating receptors via stress-induced or virus-encoded li-
gand on target cells; however, identification of the
activating NK cell receptors and ligands responsible
for mediating this effect remains elusive [22].Murine studies have shown that mature NK cells
from wild-type mice transferred into a host with a dif-
ferent major histocompatibility class I environment
can be reprogrammed to their new environment
[23,24]. This might explain the increased expression
of activating KIR after HCT seen in the present
study. Mature NK cells can be reeducated as their
new environment dictates, the new environment
being allogeneic HCT and/or CMV reactivation. Of
note, MRD transplants typically do encode for the
same HLA type in donor and recipient, but it is
possible that minor histocompatibility antigens or
otherHLA ligands (eg, nonclassical HLA-G) could in-
fluence this enhanced expression.
What specific CMV-associated factors can influ-
ence KIR gene expression? KIR genes are known to
be regulated by epigenetic factors [25-27], and viral
or host factors might have some effect. Our findings
demonstrate that at steady-state levels, normal individ-
uals have varying levels of nonexpression; this should
be explored in more detail through analysis of known
epigenetic markers. Although the promoter regions
for KIR2DS2 and KIR2DS4 are incompletely under-
stood, coding regions for these genes (chromosome
19) are known to be highly methylated [25-28]. In
addition, Cichocki et al. [29] recently suggested that
the antisense transcripts mediate KIR transcriptional
silencing through a novel PIWI-like 28-bp small
RNA. An investigation of whether variations in expres-
sion in our model of CMV post-HCT are due to such
cellular events is of interest. In our study design, early
time points afterHCTwere not fully explored, and it is
possible that the factors affecting cell differentiation
early after HCT also could significantly affect KIR
gene expression and alter CMV reactivation.ACKNOWLEDGMENTS
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